Cogent Biosciences Files Prospectus for At-The-Market Offering Of Up To $400M In Common Stock
Up to $400,000,000COMMON STOCKWe have entered into a Sales Agreement with Guggenheim Securities, LLC ("Guggenheim Securities"), dated May 6, 2022, as amended by that certain Amendment No. 1 to Sales Agreement,
Cogent Biosciences is getting permission to sell up to $400 million of its company ownership pieces to raise money for its business. When a company does this, it means they need cash, so watch if the stock price stays steady or moves as they sell these pieces.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.